AUTL
AUTOLUS THERAPEUTICS PLC
$1.85
Earnings Summary
Revenue | $1.51Mn |
Net Profits | $-33.17Mn |
Net Profit Margins | -2201.26% |
Highlights
AUTOLUS THERAPEUTICS PLC’s revenue jumped 414.33% since last year same period to $1.51Mn in the Q2 2021. On a quarterly growth basis, AUTOLUS THERAPEUTICS PLC has generated 460.22% jump in its revenue since last 3-months.
AUTOLUS THERAPEUTICS PLC’s net profit fell -3.52% since last year same period to $-33.17Mn in the Q2 2021. On a quarterly growth basis, AUTOLUS THERAPEUTICS PLC has generated 0.28% jump in its net profits since last 3-months.
AUTOLUS THERAPEUTICS PLC’s net profit margin jumped 79.87% since last year same period to -2201.26% in the Q2 2021. On a quarterly growth basis, AUTOLUS THERAPEUTICS PLC has generated 82.2% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the AUTOLUS THERAPEUTICS PLC post its latest quarter earnings
EPS Estimate Current Quarter | -0.4 |
EPS Estimate Current Year | -0.4 |
Highlights
AUTOLUS THERAPEUTICS PLC’s earning per share (EPS) estimates for the current quarter stand at -0.4 - a 12.12% jump from last quarter’s estimates.
AUTOLUS THERAPEUTICS PLC’s earning per share (EPS) estimates for the current year stand at -0.4.
Key Ratios
Key ratios of the AUTOLUS THERAPEUTICS PLC post its Q1 2023 earnings
Earning Per Share (EPS) | 0 |
Highlights
AUTOLUS THERAPEUTICS PLC’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2023. This indicates that the AUTOLUS THERAPEUTICS PLC has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2021-09-30 | -0.51 | -0.47 | 7.84% |
2021-03-31 | -0.6 | -0.53 | 11.67% |
2021-12-31 | -0.46 | -0.51 | -10.87% |
2021-06-30 | -0.5 | -0.47 | 6% |
Company Information
Autolus Therapeutics plcis a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.
Organisation | AUTOLUS THERAPEUTICS PLC |
Headquarters | The MediaWorks, London, United Kingdom, W12 7FP |
Employees | 399 |
Industry | Health Technology |
